Molecule Information

General Information of the Molecule (ID: Mol04240)

• Name: COS-L protein ,Trypanosoma cruzi
• Synonyms: COS-L protein
• Molecule Type: Protein

Kingdom: N.A.
Phylum: Euglenozoa
Class: Kinetoplastea
Order: Trypanosomatida
Family: Trypanosomatidae
Genus: Trypanosoma
Species: Trypanosoma cruzi

Type(s) of Resistant Mechanism of This Molecule

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Dabrafenib/Trametinib

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Melanoma [ICD-11: 2C30.0] [1]

• Resistant Disease: Melanoma [ICD-11: 2C30.0]
• Resistant Drug: Dabrafenib/Trametinib
• Molecule Alteration: Expression; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: WM1366 VC R cells; melanoma; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Flow cytometry; Transcriptome assay; qPCR
• Experiment for Drug Resistance: 4-methylumbelliferyl heptanoate assay
• Mechanism Description: Altogether, BRAFi/MEKi induce immune stimulatory molecules and APM components in sensitive NRAS-mutant melanoma cells, while the expression of these molecules is reversed in the resistant NRAS-mutant melanoma cells.

Clinical Trial Drug(s) 1 drug(s) in total

Vemurafenib/Cobimetinib

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Melanoma [ICD-11: 2C30.0] [1]

• Resistant Disease: Melanoma [ICD-11: 2C30.0]
• Resistant Drug: Vemurafenib/Cobimetinib
• Molecule Alteration: Expression; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: WM1366 DT R cells; melanoma; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Flow cytometry; Transcriptome assay; qPCR
• Experiment for Drug Resistance: 4-methylumbelliferyl heptanoate assay
• Mechanism Description: Altogether, BRAFi/MEKi induce immune stimulatory molecules and APM components in sensitive NRAS-mutant melanoma cells, while the expression of these molecules is reversed in the resistant NRAS-mutant melanoma cells.

References

• Ref 1: BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms. Int J Cancer. 2024 Mar 15;154(6):1057-1072.